Roche/Genentech CMO Levi Garraway
December 14, 2021 09:00 AM EST
R&D

ASH: Roche's an­ti­body-drug con­ju­gate Po­livy added to chemo-an­ti­body com­bo boosts sur­vival in ear­ly-stage lym­phoma

Kyle Blankenship

Break­throughs in drug de­vel­op­ment have be­gun to un­lock the po­ten­tial of an­ti­body-drug con­ju­gates, ther­a­pies de­signed to bet­ter tar­get pro­teins on tu­mor cells. Genen­tech’s Po­livy has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times